Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7

Reuters

Nov 12

Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7

Sutro Biopharma Inc. announced updates on its next-generation antibody-drug conjugate $(ADC)$ pipeline during a virtual R&D Day. The company has initiated a Phase 1 clinical study for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected in mid-2026. Sutro also revealed STRO-227, its first dual-payload ADC candidate targeting PTK7, with an IND submission targeted for 2026/2027. Additionally, Sutro highlighted ongoing collaborations, including a partnership with Astellas on dual-payload immunostimulatory ADCs, with the first clinical program expected to begin in early 2026. The scientific research results and pipeline updates were presented during the event, which featured company leadership and external oncology experts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573463-en) on November 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582700613"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582700613\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582700613?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582700613","market":"us","top_or_hot":-1,"title":"Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. announced updates on its next-generation antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> pipeline during a virtual R&amp;D Day. The company has initiated a Phase 1 clinical study for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected in mid-2026. Sutro also revealed STRO-227, its first dual-payload ADC candidate targeting PTK7, with an IND submission targeted for 2026/2027. Additionally, Sutro highlighted ongoing collaborations, including a partnership with Astellas on dual-payload immunostimulatory ADCs, with the first clinical program expected to begin in early 2026. The scientific research results and pipeline updates were presented during the event, which featured company leadership and external oncology experts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573463-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. announced updates on its next-generation antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> pipeline during a virtual R&amp;D Day. The company has initiated a Phase 1 clinical study for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected in mid-2026. Sutro also revealed STRO-227, its first dual-payload ADC candidate targeting PTK7, with an IND submission targeted for 2026/2027. Additionally, Sutro highlighted ongoing collaborations, including a partnership with Astellas on dual-payload immunostimulatory ADCs, with the first clinical program expected to begin in early 2026. The scientific research results and pipeline updates were presented during the event, which featured company leadership and external oncology experts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573463-en) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL1bhmBp:1","article_id":"2582700613","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582700613","pubTimestamp":1762959614,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sutro Biopharma Inc. announced updates on its next-generation antibody-drug conjugate  pipeline during a virtual R&D Day. The company has initiated a Phase 1 clinical study for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected in mid-2026. Sutro also revealed STRO-227, its first dual-payload ADC candidate targeting PTK7, with an IND submission targeted for 2026/2027. Additionally, Sutro highlighted ongoing collaborations, including a partnership with Astellas on dual-payload immunostimulatory ADCs, with the first clinical program expected to begin in early 2026. The scientific research results and pipeline updates were presented during the event, which featured company leadership and external oncology experts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","STRO":"Sutro Biopharma Inc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"Sutro Biopharma推出STRO-227，作为首个靶向PTK7的双有效载荷ADC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"STRO":0.9},"content_text":"Sutro Biopharma Unveils STRO-227 as First Dual-Payload ADC Targeting PTK7\n    \n\nSutro Biopharma Inc. announced updates on its next-generation antibody-drug conjugate $(ADC)$ pipeline during a virtual R&D Day. The company has initiated a Phase 1 clinical study for STRO-004, a potential best-in-class Tissue Factor ADC, with initial data expected in mid-2026. Sutro also revealed STRO-227, its first dual-payload ADC candidate targeting PTK7, with an IND submission targeted for 2026/2027. Additionally, Sutro highlighted ongoing collaborations, including a partnership with Astellas on dual-payload immunostimulatory ADCs, with the first clinical program expected to begin in early 2026. The scientific research results and pipeline updates were presented during the event, which featured company leadership and external oncology experts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573463-en) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}